Glucagon-like peptide-1 receptor agonists may delay the incidence of major adverse cardiovascular events by an average of 0.6 months over a 4-year period in people with type 2 diabetes, meta-analysis data suggest.
Adding a weekly semaglutide injection in people already using basal insulin to treat type 2 diabetes avoids the need for prandial insulin, show the SUSTAIN 11 findings.
Adding daily empagliflozin to closed-loop insulin delivery improves time in range but also increases ketone levels in people with type 1 diabetes, shows a randomized trial.
Researchers have identified four simple clinical criteria that can be used to predict the likelihood of insulin allergy and guide decisions about the need for confirmatory allergy testing.
People with type 2 diabetes who have suboptimal glycemic control on metformin alone may benefit from add-on treatment with the dual-acting glucokinase activator dorzagliatin, report the DAWN investigators.
Researchers recommend using different BMI or age thresholds for type 2 diabetes screening in ethnic minority groups, on finding that a single threshold may miss many cases in non-White Americans.
People who lose weight while taking semaglutide 2.4 mg regain two-thirds of what they lost during the first year after stopping the medication, shows the STEP 1 extension study.
The risk for kidney disease has fallen for people diagnosed with type 1 diabetes in more recent decades, but is still substantial and has stopped decreasing, study results suggest.
Transdermal capillary blood collection produces samples in which C-peptide can be reliably measured, removing the need for venous blood sampling, report researchers.
Less than 10% of people with self-reported diabetes in India meet optimal treatment targets for glycated hemoglobin, blood pressure, and low-density lipoprotein cholesterol control combined, show data from the ICMR-INDIAB study.
Italian researchers have compared outcomes of children and adults with type 1 diabetes using Medtronic MiniMed 780G and the Tandem Control IQ closed-loop insulin delivery systems in real-world practice.
Results of a phase 1 study show that a concentrated version of insulin aspart not only provides a smaller injection volume but also has a more rapid onset of action than the standard version.
Early findings from the Hypo-METRICS trial indicate that people with diabetes are unaware on most of the occasions that their blood glucose dips into the hypoglycemic range.
Poor glycemic control is associated with an impaired immune response to vaccination against SARS-CoV-2 and an increased risk for breakthrough infections in people with type 2 diabetes, report researchers.
Tirzepatide improves glucose control more than semaglutide in people with type 2 diabetes by improving beta-cell function as well as boosting insulin sensitivity and reducing glucagon secretion, shows a randomized trial.
Study findings published in BMC Medicine show that increasing albuminuria, decreasing estimated glomerular filtration rate, and worsening stages of chronic kidney disease are independently associated with increased risk for stroke in people with type 2 diabetes.
The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.
Implementing a subcutaneous insulin protocol for the treatment of diabetic ketoacidosis significantly reduces intensive care admissions and readmission to hospital within 30 days of discharge without increasing hypoglycemia, research shows.